Dementia Treatment Market – By Drug Class (Cholinesterase, NMDA Receptor, Glutamate, Combination Drugs, MOA), Indication (Alzheimer’s Disease, Parkinson Disease, Vascular, FTD), Route of Administration, Distribution Channel & Forecast, 2024 – 2032

Dementia Treatment Market – By Drug Class (Cholinesterase, NMDA Receptor, Glutamate, Combination Drugs, MOA), Indication (Alzheimer’s Disease, Parkinson Disease, Vascular, FTD), Route of Administration, Distribution Channel & Forecast, 2024 – 2032

Dementia Treatment Market size is projected to expand at 7.6% CAGR from 2024 to 2032, led by the rising government initiatives alongside technological innovations. Lately, numerous governments worldwide are investing in R&D for providing grants and expedite the approval process for new therapies. This support is fostering advancements in early diagnosis, personalized treatment, and improved care methods.

Moreover, technological innovations, such as AI-driven diagnostics and advanced drug delivery systems are transforming dementia care to enhance the quality of life for patients and reduce the burden on caregivers. For instance, in May 2023, the U.S. FDA announced the supplemental approval of Rexulti (brexpiprazole) for treating agitation in Alzheimer's disease. This marked the introduction of the first FDA-approved treatment for this specific dementia-related symptom.

The overall market is segregated into drug class, indication, route of administration, distribution channel, and region.

Based on drug class, the dementia treatment market value from the glutamate inhibitors segment is estimated to rise at a significant rate from 2024 to 2032 due to their ability to target the neurotransmitter glutamate which can be overly active in neurodegenerative conditions. By reducing the excessive activity of glutamate, these inhibitors protect brain cells from damage and improve cognitive function. Researchers are also exploring these inhibitors to help manage symptoms and potentially slow the disease progression.

Dementia treatment industry share from the injectable route of administration segment is anticipated to expand at a substantial growth rate up to 2032, owing to the rising need for offering more targeted and manageable solutions to those living with dementia. Researchers are developing and testing various injectable medications to target underlying causes and symptoms of dementia more effectively. Several treatments are also designed to deliver drugs directly into the bloodstream or nervous system to improve efficacy and minimize side effects.

Regionally, the Europe dementia treatment market size is projected to witness robust growth between 2024 and 2032, on account of the aging population and increasing public awareness campaigns. As the number of elderly individuals is growing in the region, there is rising demand for effective dementia care solutions. Public awareness campaigns are educating people about dementia for encouraging early diagnosis and support research into new treatments, adding to the industry growth in Europe.